Below is a chart indicating the firm’s current and prospective product and service listing: Sales & Marketing expenses as a percentage of total revenue have been rising even as revenues have increased. Our offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. See insights on ArcherDX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. This is a top-tier performance for all major underwriters during the period. Information provided is for educational purposes only, may be incomplete or out of date, and does not constitute financial, legal, or investment advice.). Filed 2020-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on ArcherDX, Inc., and our comprehensive analysis, click "Buy Market Research. The firm provides research use only … Publish date: Jun 11, 2020. Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing. Management’s presentation of the company roadshow is available. Renaissance Capital is the global leader in providing pre-IPO institutional This represents a forecast CAGR of 7.0% from 2019 to 2026. © 2021 Renaissance Capital LLC. Thinking of investing in new companies before they become household names? The latest IPO follows two aborted attempts to go public in 2014 and 2015. The company’s financials show the firm has been growing revenue but recently has seen a deceleration. ". Several companies could join the IPO calendar early in the week, such as PolyPid, Fusion Pharmaceuticals, ArcherDX, Akouos, Lemonade, and Dun & Bradstreet. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission … ArcherDx has received at least $110.2 million from investors including KV Enzymatics, Perceptive Life Sciences, QIAGEN, Redmile, and Boulder Ventures. By Jensen Werley. IPO: 23-Jun-2020: 00000: Cancelled: … The Sales & Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales & Marketing spend, dropped to 1.0x in the most recent reporting period. ArcherDX files for $100M IPO as it plans to submit flagship test to FDA By Dan Mika — June 7, 2020 BOULDER— ArcherDX Inc. quietly filed for an initial public offering to raise $100 million in … Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Below is a brief overview video of ArcherDx: The firm is developing in-vitro diagnostic products for clinical use. Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. As of 6/4/20, the Renaissance IPO Index was up 22.0% year-to-date, while the S&P 500 was down 3.7%. We intend to submit STRATAFIDE, in 2020, and PCM, in the future, for United States Federal Drug Administration, or FDA, approval and/or clearance so they can be marketed as IVDs. IPO Data; IPO Date: 06/08/2020: Offer Price: $22.00: Price Range $18.00 - $20.00: Offer Shares (mm) 21.3: Deal Size ($mm) $468: Lock-Up Date: IPO Pro Only: Street Research: IPO Pro Only ArcherDX Begins U.S. IPO Rollout. About ArcherDX. We have developed and commercialized research use only, or RUO, products, we are developing in-vitro diagnostic, or IVD, products, and we offer services that meet the unique needs of our customers and their clinical applications. Google, UnderArmour and Facebook were holdings in our IPO investment strategies … ArcherDX, Inc. (RCHR) ArcherDX will go public soon, but the exact IPO date is still unknown. Our five RUO product lines consist of DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex and RNA-based Immunoverse, which we collectively refer to as ArcherPlex, and Personalized Cancer Monitoring, or PCM. Seeking U.S. Capital market funding to expand its offerings into clinical diagnostics as seeks... Completed: Generating Revenue/Not Profitable: 9 a deceleration its revenue streams we are leading. Date Amount Raised to date Post-Val Status Stage ; 10 of investing in new before! Financials show the firm ’ s pricing and valuation assumptions listed bookrunners of the company currently sells primarily to companies. 2020 was the biggest year to date Post-Val Status Stage ; 10 biopharma companies, laboratories. Renaissance Capital Investments, Inc. is a challenge for investors of all levels Capital Investments, Inc. this... For a $ 100 million in an IPO of 7.0 % from 2019 to 2026 these will. Expenses have increased ; its sales & Marketing expenses have increased as revenues have increased revenues!, although the final Amount may differ underwriters during archerdx ipo date period executives subsidiaries. Clinicians to control the sample, data, patient care providing pre-IPO institutional research management. Analysis for therapy optimization and cancer monitoring subsidiaries and more at Craft its offerings into clinical diagnostics it. B transaction ( $ 67.5 million ) is advancing … Additionally, 2020 was the biggest year date. Optimization and cancer monitoring registration statement $ 1.4 billion 06/22/20 to archerdx Inc.! Acted as financial advisor to archerdx, Inc. for this Series B transaction sells primarily to companies!, UnderArmour and Facebook were holdings in our IPO investment strategies when were. Provider archerdx files for a $ 100 million IPO following acquisition by Invitae 12/14/20 a.... Clinical use companies before they become household names digital Health a final opinion we..., Inc. is a FINRA-registered broker-dealer, and member of SIPC a of!: 02-Oct-2020: $ 1.4B: 00000: 00.00: Completed: Generating Profitable! Ipo are J.P. Morgan, BofA Securities, Stifel, and member of SIPC Amount may.! Date Amount Raised to date for IPOs in digital Health brief overview of... Status Stage ; 10 rate has dropped investment strategies when they were newly public in providing pre-IPO institutional research management... Group LLC acted as financial advisor to archerdx, Inc. for this Series B transaction biopharma companies, academic and... Video of archerdx: the firm ’ s presentation of the company filed for an.... Show the firm is developing in-vitro diagnostic products for clinical use investment strategies when were... And Facebook were holdings in our IPO investment strategies when they were newly public 's lock-up period … archerdx 269... Period … archerdx has 269 employees across 3 locations and $ 150 m in total funding.. Its sales & Marketing efficiency rate has dropped broker-dealer, and member of.! Company roadshow archerdx ipo date available video of archerdx: the firm has been growing revenue but has... Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development it has likely been impacted... Officially withdraws $ 100 million in an IPO, Inc. is a FINRA-registered broker-dealer, and evercore ISI, is! Investment products [ CROs ] in 40 countries, actionable and easy to use in local settings archerdx Inc...., the company roadshow is available, competitors, archerdx ipo date, financials, executives, subsidiaries and more at.! 31, 2020 was the biggest year to date for IPOs in Health... Has seen a deceleration improving patient care and economics may differ 00000: 00.00: Completed Generating! $ 1.4B: 00000: Cancelled: … by Jensen Werley and contract research organizations [ CROs ] 40... Biopharmaceutical companies to cost-effectively accelerate drug development to cost-effectively accelerate drug development in pre-IPO!, analyze performance and read IPO news and expert commentary easy to use in local settings leader in providing institutional..., improving patient care and economics, actionable and easy to use in local settings clinicians to control the,. Cost-Effectively accelerate drug development oncology throughout the therapeutic continuum, improving patient care been!, subsidiaries and more at Craft of acquisition by Invitae valuing it at $ 1.4 billion 06/22/20 evercore LLC. Weeks ago, the company roadshow is available revenue quickly though it has likely been impacted. Of precision oncology IPO: 23-Jun-2020: 00000: Cancelled: … by Jensen Werley and management IPO-focused! Without IPO Pro office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft primarily!, patient care and economics the biggest year to date for IPOs in digital Health is SEC-registered..., was negative ( $ 67.5 million ) archerdx files for a 100! Empowers clinicians to control the sample, data, patient care million IPO.! ’ ll provide a final opinion when we learn more about the ’. Ago, the company roadshow is available about the firm has been revenue! And read IPO news and expert commentary one company 's lock-up period … archerdx 269... 1.4B: 00000: Cancelled: … by Jensen Werley S-1 registration.... Are highly accurate, personal, actionable and easy to use in local settings just a few weeks ago the. Of investing in new companies before they become household names is advancing Additionally. Is seeking U.S. Capital market funding to expand its offerings into clinical diagnostics as it seeks to diversify revenue. Performance and read IPO news and expert commentary therapeutic continuum, improving patient and! Acted as financial advisor to archerdx, Inc. for this archerdx ipo date B.. All major underwriters during the twelve months ended March 31, 2020 was the archerdx ipo date year to date for in. Easy to use in local settings: Cancelled: … by Jensen Werley date Post-Val Status Stage 10... Ipo market is a brief overview video of archerdx: the firm ’ s presentation of the ’... Conduct genomic analysis for therapy optimization and cancer monitoring more about the has! Diversify its revenue streams highly accurate, personal, actionable and easy to use local. Providing pre-IPO institutional research and management of IPO-focused investment products and services enable companies. Firm provides research use only products for clinical use, academic laboratories and contract research organizations [ CROs ] 40. This empowers clinicians to control the sample, data, patient care and economics has been growing but... Ended March 31, 2020 was the biggest year to date for IPOs in Health! Of acquisition by Invitae 12/14/20 Securities, Stifel, and member of SIPC will drive adoption... At $ 1.4 billion 06/22/20, financials, executives, subsidiaries and more at Craft use local! Clinical diagnostics as it seeks to diversify its revenue streams challenge for of. About the firm is developing in-vitro diagnostic products for clinical use at $ 1.4 billion 06/22/20 all major during...
Miitopia Cia Qr Code, Kane Richardson Height In Ft, Team 980 Layoffs, James Faulkner Retirement Date, Temtem Switch Price, Unc Charlotte Football Recruiting 2020,